Novo Nordisk misses the mark in key obesity Phase 3 trial: Cagrisema showed a 20.4% weight loss at 68 weeks compared to 2.4% for placebo, but expectations were at 25% to clearly differentiate from the 20.9% shown by Tirzepatide $NVO $LLY www.novonordisk.com/content/nnco... - ThreadSky | a Reddit-style client for Bluesky

jordixiol.bsky.social • 73 days ago

Novo Nordisk misses the mark in key obesity Phase 3 trial: Cagrisema showed a 20.4% weight loss at 68 weeks compared to 2.4% for placebo, but expectations were at 25% to clearly differentiate from the 20.9% shown by Tirzepatide

$NVO $LLY

https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915082

Comments